Commentary
A new model for ductal carcinoma in situ suggests strategies for treatment
-
Correspondence: William J Gullick W.J.Gullick@ukc.ac.uk
Department of Biosciences, University of Kent at Canterbury, UK
Breast Cancer Res 2002, 4:176-178 doi:10.1186/bcr447
Published: 19 July 2002Abstract
Human ductal carcinoma in situ (DCIS) of the breast is now diagnosed quite frequently, due largely to the introduction of mammographic screening. It has been shown in a cell culture system that activation of c-erbB-2, but not the epidermal growth factor receptor, results in a DCIS-like phenotype. Since overexpression of c-erbB-2 occurs in 60% of DCIS, this suggests that it could be a target for treatment in this disease.